Igm Biosciences Inc (IGMS)

$1.27 -0.06 (-4.51%)
Market Cap 79.50M
Revenue (ttm) 2.68M
Net Income (ttm) -195.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,305.97%
Debt to Equity Ratio 0.00
Volume 365,700
Avg Vol 170,062
Day's Range N/A - N/A
Shares Out 59.78M
Stochastic %K 48%
Beta 0.61
Analysts Hold
Price Target $1.87

Latest News on IGMS

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

Jan 9, 2025, 2:27 PM EST - 5 months ago

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

Jan 9, 2025, 1:00 PM EST - 5 months ago

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 7:00 AM EST - 7 months ago

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at Three Upcoming Investor Conferences

Nov 4, 2024, 7:00 AM EST - 7 months ago

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

Oct 1, 2024, 11:41 AM EDT - 8 months ago

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Oct 1, 2024, 11:40 AM EDT - 8 months ago

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

Oct 1, 2024, 8:00 AM EDT - 8 months ago

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Oct 1, 2024, 7:54 AM EDT - 8 months ago

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Sep 30, 2024, 4:01 PM EDT - 8 months ago

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

Sep 10, 2024, 4:05 PM EDT - 9 months ago

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 7:00 AM EDT - 10 months ago

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:10 PM EDT - 1 year ago

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Apr 17, 2024, 8:30 AM EDT - 1 year ago

IGM Biosciences Announces Refocusing of Sanofi Collaboration

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 10, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Feb 12, 2024, 3:09 PM EST - 1 year ago

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Medivir to present at the Carlsquare Equity Research Investor Day

Dec 6, 2023, 2:44 AM EST - 1 year ago

Medivir to present at the Carlsquare Equity Research Investor Day

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Dec 5, 2023, 4:01 PM EST - 1 year ago

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Dec 1, 2023, 5:32 AM EST - 1 year ago

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Nov 27, 2023, 3:52 AM EST - 1 year ago

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Nov 22, 2023, 2:46 AM EST - 1 year ago

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

Nov 21, 2023, 2:48 AM EST - 1 year ago

Medivir to present at the Erik Penser Bank Company Event

IGM Biosciences Announces Third Quarter 2023 Financial Results

Nov 13, 2023, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Third Quarter 2023 Financial Results

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Nov 13, 2023, 3:49 AM EST - 1 year ago

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

IGM Biosciences to Present at Two Upcoming Investor Conferences

Nov 7, 2023, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at Two Upcoming Investor Conferences

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Oct 25, 2023, 2:46 AM EDT - 1 year ago

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Nomination Committee of Medivir appointed

Oct 23, 2023, 2:48 AM EDT - 1 year ago

Nomination Committee of Medivir appointed

Change in Medivir's Board of Directors

Oct 20, 2023, 9:29 AM EDT - 1 year ago

Change in Medivir's Board of Directors

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

Oct 5, 2023, 7:29 AM EDT - 1 year ago

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

Oct 3, 2023, 4:05 PM EDT - 1 year ago

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Sep 11, 2023, 5:41 AM EDT - 1 year ago

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Sep 7, 2023, 3:46 AM EDT - 1 year ago

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 6, 2023, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Sep 4, 2023, 2:52 AM EDT - 1 year ago

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Sep 1, 2023, 3:20 AM EDT - 1 year ago

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Aug 14, 2023, 3:03 AM EDT - 1 year ago

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Aug 7, 2023, 2:46 AM EDT - 1 year ago

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

IGM Biosciences Announces Second Quarter 2023 Financial Results

Aug 3, 2023, 4:10 PM EDT - 1 year ago

IGM Biosciences Announces Second Quarter 2023 Financial Results

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 3, 2023, 4:01 PM EDT - 2 years ago

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

Jun 22, 2023, 7:58 AM EDT - 2 years ago

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

IGM Announces Proposed Public Offering and Concurrent Private Placement

Jun 21, 2023, 5:17 PM EDT - 2 years ago

IGM Announces Proposed Public Offering and Concurrent Private Placement

Medivir's patent application for fostrox approved in China

Jun 19, 2023, 4:12 AM EDT - 2 years ago

Medivir's patent application for fostrox approved in China

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Jun 2, 2023, 5:30 PM EDT - 2 years ago

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Jun 2, 2023, 3:22 AM EDT - 2 years ago

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima